Fred Hutchinson Cancer Center
1100 Fairview Ave N, Seattle, WA, 98109, United States
Overview
Fred Hutchinson Cancer Research Center provides research services for the prevention, early detection, and treatment of cancer and other diseases in the United States and other countries. The research center is engaged in researches to prevent, detect, and treat cancer, HIV/AIDS, and other life-threatening diseases. Its activities in the areas of diseases and research cover fundamental research, prevention, early detection, treatment and cures, and survivorships. Researchers of Fred Hutchinson Cancer Research Center pioneered bone-marrow transplantation for leukemia and other blood diseases. This research has cured thousands of patients worldwide and has boosted survival rates for certain forms of leukemia from zero to 85 percent. Fred Hutchinson Cancer Research Center was incorporated in 1971 and is based in Seattle, Washington.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Biotechnology
- Consulting
- Health Care
- Health Diagnostics
- Hospitality
- Medical
- Oncology
- Pharmaceutical
Investment portfolio
- Ensoma
Participated · Series B · Jan 2023
Ensoma is a Boston-based biotechnology company focused on engineering hematopoietic stem cells directly inside the body to create durable genetic medicines for genetic diseases, immune disorders, and cancer. Its platform uses high-capacity virus-like particles (VLPs) that selectively target HSCs and can deliver up to 35 kb of genetic cargo, enabling single-base edits through large multi-gene insertions. The company combines these VLPs with proprietary base-editing and gene-integration systems, aiming for one-time intravenous administration. Proceeds from its latest financing will fund a Phase 1/2 clinical trial of lead candidate EN-374 for X-linked chronic granulomatous disease and support platform expansion into immuno-oncology and sickle cell programs. Ensoma’s strategy centers on creating off-the-shelf, non-myeloablative treatments that avoid the complexity and cost of ex vivo cell processing. The firm’s board now includes a Gilead appointee following the strategic investment. No financial metrics or commercial revenues have been disclosed to date.
- Affini-T Therapeutics
Participated · Equity · Mar 2022
Affini-T’s proprietary platform selects and engineers T cells and combines highly active TCRs with synthetic biology switches to enhance T cell function, durability and tumor infiltration. The company is initially focused on targeting mutant variants of KRAS, a prevalent oncogenic driver mutation in solid tumors. Its platform aims to rewrite the rules of the tumor microenvironment to produce sustained clinical responses in hard-to-treat cancers such as lung, colorectal and pancreatic cancer. Affini-T plans to operationalize its discovery engine and drive multiple oncogene driver programs into the clinic while pursuing complementary technology licenses to bolster its cell therapy platform. To enable and accelerate growth the company has established a bi-coastal U.S. presence with research labs in Seattle and headquarters and manufacturing infrastructure in Boston. The management team and scientific advisory board include leaders from industry and top research institutions, underscoring the company’s emphasis on translational cellular engineering.